19:21 , Sep 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro and mouse studies identified a hedgehog pathway inhibitor that could help treat medulloblastoma. Optimization and testing in mouse fibroblast cell-based assays of a previously identified dihydrobenzooxazocin analog yielded a compound...
18:09 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting GLI1 alone or in combination with PI3K could help treat squamous cell carcinoma (SCC) of the lung. In lung tissue samples from patients,...
16:32 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Myeloproliferative disorder Patient sample and mouse studies suggest inhibiting GLI1 -expressing cells could help treat myeloproliferative neoplasms (MPN). In patients with higher grades of MPN, bone marrow samples had a higher percentage of GLI1-expressing...
21:43 , Feb 2, 2017 |  BC Innovations  |  Translation in Brief

Repairing repair

A Stanford team has figured out one reason diabetics have impaired bone healing, and devised a method of boosting skeletal stem cell expansion to correct the complication. The January study in Science Translational Medicine builds...
17:50 , Feb 1, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Bone repair Patient sample and mouse studies suggest IHH and SHH could help treat diabetes-associated bone fractures. In patients undergoing joint replacement, levels of IHH and GLI family zinc finger 1 (GLI1) were lower...
14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: GLI family zinc finger 1 (GLI1)

Cardiovascular disease INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting GLI1 could help treat atherosclerosis associated with chronic kidney disease (CKD). In patient samples of arterial atherosclerotic plaques and calcified tunica media, levels of...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

SUBA-Itraconazole: Interim Phase IIb data

Interim data from 13 patients with BCC nevus syndrome (Gorlin Syndrome) in the open-label, U.S. Phase IIb SCORING trial showed that twice-daily 150 mg oral SUBA-Itraconazole for >=16 weeks reduced target tumor burden by >30%...
07:00 , May 26, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: GLI family zinc finger 1 (GLI1); GLI3; suppressor of fused homolog (SUFU)

Hepatic disease INDICATION: Hepatic Mouse and cell culture studies suggest promoting expression of GLI1 and GLI3 or inhibiting SUFU could help treat hepatic steatosis. Hepatocyte levels of GLI1 and GLI3 were lower in three mouse...